To evaluate associations between laboratory-confirmed 2009 H1N1 influenza infection and obstetric and neonatal outcomes. STUDY DESIGN: A multicenter cohort study was performed comparing laboratory-confirmed cases of 2009 H1N1 infection during pregnancy (N ¼ 142) with matched controls (N ¼ 710). Subanalysis was also performed comparing severely infected (hospitalized) women with controls. RESULT: No outcome differences were noted in comparing all women with H1N1 with controls. Women with severe infection had a higher incidence of delivering a small for gestational age (SGA) infant: 18.8% (6/32) versus 7.4% (52/707), adjusted odds ratio 2.35 (95% confidence interval 1.03, 5.36, P ¼ 0.02). Mean birth weight was 3013.0 g among severely infected women and 3223.3 g in controls (P ¼ 0.08), and incidence of preterm delivery was 25.0% (8/32) and 11.6% (82/710) (P ¼ 0.08), respectively. CONCLUSION: Pregnant women with mild clinical illness secondary to 2009 H1N1 were not at a greater risk of adverse pregnancy outcomes. However, severely infected women were more likely to deliver SGA infants.
INTRODUCTION
Morbidity and mortality due to influenza is increased during pregnancy. Descriptions of this phenomenon emerged after the 1918 influenza pandemic, during which 50% of affected pregnant women developed pneumonia and 27% died. 1 These findings were validated during the 2009 H1N1 pandemic. Pregnancy was found to be a risk factor for severe disease, hospitalization and death compared with the general population. 2, 3, [4] [5] [6] Various domestic investigations have demonstrated heightened rates of hospitalization during pregnancy and the early postpartum period and note that 5% of all deaths from H1N1 influenza occurred among pregnant women who represent only 1% of the population. [2] [3] [4] International data also support these heightened risks. 5, 6 Less frequently studied is the association of influenza with adverse pregnancy and neonatal outcomes. In the 1918 pandemic, 26% of women without pneumonia and 52% of women with pneumonia miscarried or delivered prematurely. 1 More recent reports note that women with a respiratory-related hospitalization during influenza season delivered infants with lower birth weights and at increased risk of being small for gestational age (SGA); 7 a separate study confirmed an association between seasonal influenza and increases in SGA infants. 8 In addition, several studies have found an association between influenza vaccination and lower rates of SGA and prematurity. 9, 10 The H1N1 influenza pandemic provided a contemporary opportunity to examine the effects of influenza infection on pregnancy outcomes. Most prior investigations have been case series of women with severe maternal disease and have lacked cases with milder disease or a noninfected comparison group. 4, 11, 12 The goals of this investigation were to evaluate all severe and nonsevere laboratory-confirmed cases of 2009 H1N1 influenza from three large US academic centers and compare their pregnancy outcomes with matched controls. The specific aim was to determine whether laboratory-proven H1N1 influenza infection during pregnancy was associated with adverse pregnancy and neonatal outcomes.
METHODS
A multicenter observational cohort study was conducted at MageeWomens Hospital of the University of Pittsburgh Medical Center, the University of Colorado Denver and the University of Washington. Institutional review board approval was obtained at each site.
Pregnant women with positive testing for H1N1 influenza at the three sites were identified. At the University of Pittsburgh and the University of Washington, all inpatient and outpatient pregnant and postpartum women within 6 weeks of delivery who tested positive for H1N1 influenza were identified through an infection control database. In Pittsburgh, cases were monitored between September 2009 and May 2010, and in Washington, cases were collected between July 2009 and January 2010.
Women at both sites were tested through the emergency department, the labor and delivery unit, the antepartum and postpartum floors and outpatient offices. Five control participants were identified for each case by randomly selecting women who delivered at the same institution with an estimated date of delivery within the same calendar month. Maternal demographic data, pregnancy characteristics and obstetric and neonatal outcomes of cases and controls were collected from a research database in Pittsburgh and by chart review in Washington. The course of maternal influenza infection including treatment with oseltamivir was determined by chart review.
At the University of Colorado, participants were identified through a postpartum questionnaire study addressing influenza vaccination and infection. Full methods of recruitment are described in detail elsewhere. 13 Briefly, all inpatient postpartum women at that institution between 3 November 2009 and 3 May 2010 were eligible, and of these, 52% of women participated. Women who experienced intrauterine fetal demise (N ¼ 1) and those delivering at o24 weeks were excluded because of incomplete data on pregnancy outcomes at these early gestational ages in the controls. H1N1 positivity was determined from an infection control database. Controls were selected in the same manner as the other sites. Maternal demographics, medical characteristics and obstetric and neonatal outcomes were obtained from a research database. Participant patients from the University of Colorado were compared with nonparticipant women who delivered during the same time period at the same institution. Participants were more likely to be primiparous (43% vs 36%, Po0.01) and were less likely to have an infant in the neonatal intensive care unit (12% vs 20%, Po0.01). 13 Oseltamivir treatment data and details of maternal course were not complete from the University of Colorado and are not included. Criteria for initial testing were the same at all sites. Patients reporting one or more symptoms of influenza, including fever, cough, sore throat, rhinorrhea or nasal congestion, body aches, headache, fatigue or diarrhea, were tested. Decision for hospitalization was made by individual providers. Admission criteria did not differ between sites and included one or more of the following: fever, requiring supplemental oxygen, bronchodilators or need for additional antibiotic therapy. At all sites, race was determined by self-report and gestational age was determined according to the standard American College of Obstetricians and Gynecologists criteria.
14 Hypertensive disorders of pregnancy were defined as gestational hypertension, pre-eclampsia and eclampsia.
Cases of the Universities of Pittsburgh and Washington were all confirmed to be influenza A, subtype novel H1N1 by real-time PCR. In brief, total nucleic acid was extracted from respiratory specimens using a BioMerieux EasyMag (Cambridge, MA, USA) automated nucleic acid extractor. Influenza virus detection was performed using a qualitative, multiplex real-time PCR assay with primers and fluorescently labeled TaqMan (Life Technologies, Grand Island, NY, USA) probes specific to influenza A and influenza B virus as further delineated. 15 At the University of Colorado, all symptomatic women were initially tested with a rapid influenza diagnostic test (RIDT), an antigen detection test, for influenza A. Those with positive testing were presumed positive for novel H1N1 as no other influenza virus was noted in circulation at that time. 16 Any negative RIDT result was reflexed to PCR testing and some were confirmed to have H1N1 influenza A after a previous negative RIDT. Although these two methods (real-time PCR and RIDT) of laboratory confirmation differ, both are considered valid approaches for making the diagnosis of H1N1.
Data from all cases and control patients from the three sites were combined into a single data set for analysis. Primary outcomes were birth weight, gestational age at delivery, incidence of preterm delivery (delivery at o37 completed weeks) and incidence of SGA infant less than tenth percentile as per Hadlock et al. 17 Secondary outcomes included incidence of Cesarean section, induction of labor and admission to neonatal intensive care unit. Because of the inconsistent data (and very low numbers) available regarding delivery at o24 weeks of gestation and intrauterine fetal demises (among both cases and controls), this outcome was not included in the analysis.
Subgroup analyses were performed. Women with severe H1N1 influenza infection, defined as requiring hospitalization (N ¼ 32), were separately compared with controls. Women who received early oseltamivir administration (within 48 h of symptoms) were compared with women with delayed administration to investigate for treatment timing associations. Patients without a clear record of treatment were excluded in this subanalysis. Pregnancy outcomes were also analyzed by trimester of infection.
Continuous variables were compared using Student's t-test and categorical variables were compared using w 2 test or Fisher's exact test where appropriate. Multivariable analyses were performed using linear regression for continuous variables and logistic regression for categorical variables. All clinically relevant variables were considered in the models based on a priori knowledge. In order to create a parsimonious model that was appropriate for the most rare primary outcome (SGA), models were limited to the exposure of interest, H1N1 status and no more than four covariates. Site was added a priori, and other covariates were selected with backward/stepwise variable selection. All models were fit with the same covariates: H1N1 case status, study site, age, multiple gestation and hypertensive disorders of pregnancy. Model fit was also tested for each outcome, and a more restricted model for preterm birth was utilized to improve the fit for that outcome. We additionally replicated all analyses after excluding cases of multiple gestation. Results were unchanged and thus multiples were included, and accounted for as a covariate. Models were additionally adjusted for maternal race and the composite variable of any chronic medical condition to ensure that these were not significant contributors. Results were unchanged, and therefore these variables are not included in the final models. Given the differing methodology at the sites and its potential impact on results, mixed models, with site as a random effect, were used to ensure that site differences were adequately evaluated. Results were unchanged with this analysis, and hence regression results are presented from linear and logistic models that included a site variable. An a priori two-tailed significance level of Pp0.05 was chosen. SAS (SAS Institute, Cary, NC, USA) was used for analyses. Given the available sample size of women with influenza, we had 80% power to detect a 26 g difference in birth weight, a 0.11-week difference in gestational age at delivery, an 8% difference in the incidence of preterm delivery and a 6% difference in incidence of SGA between the H1N1 and control groups.
RESULTS
In all, 78 cases of laboratory-confirmed 2009 H1N1 influenza were identified at University of Pittsburgh, 27 at University of Washington and 37 at University of Colorado, for 142 total cases. These were matched to a total of 710 controls. Of the University of Pittsburgh cases, 17 have been included in a recently published investigation of influenza-like illness in pregnancy. 18 The demographic and pregnancy characteristics of all 142 cases were compared with the 710 controls ( Table 1) . Black race was significantly more prevalent in the influenza group compared with the controls. Medical comorbidities were compared between H1N1 cases and controls (Table 2) . Chronic hypertension, prepregnancy diabetes, seizure disorder and asthma all had a significantly higher prevalence among the cases than among the controls. These same comorbidities (as well as gestational diabetes) were also noted to have a significantly higher prevalence among severe H1N1 cases. Women with severe H1N1 also had a higher mean pregravid weight than control patients (176.8±55.7 lb in women with severe influenza and 149.5±36.7 lb in control women, Po0.01).
Overall, no associations between H1N1 infection and adverse pregnancy outcomes were noted for all (N ¼ 142) H1N1 cases ( Table 3 ). The subgroup of nonseverely infected women (N ¼ 110) was also compared with the control group (N ¼ 710) and there were no differences noted among demographics or pregnancy outcomes.
Cases of severe H1N1 infection were subsequently compared with control patients. A total of 32 women comprised the 'severe infection' cohort: 17 women from Pittsburgh (22% of Pittsburgh patients), 11 women from Seattle (41% of Seattle patients) and 4 women from Colorado (11% of Colorado patients; P ¼ 0.02 for comparison among sites). Very severe infections, necessitating intensive care unit admission (n ¼ 5), intubation (n ¼ 3) or vasopressor support (n ¼ 1), were less frequent.
The results of the analyses of severe infection are presented in Table 4 . The odds of delivering an SGA infant were more than twice as likely in the severely affected cohort (18.8% versus 7.4%, adjusted odds ratio (OR) of 2.35 (95% confidence interval (CI) 1.03, 5.36)). Additional adjustment for maternal race and presence of any chronic condition did not change these estimates. Incidence of preterm delivery was more than twice in the severely infected and control groups (25.0% and 11.6%), respectively, but did not reach statistical significance (adjusted OR 2.07, 95% CI 0.88, 4.84). Mean birth weight was 3013.0 g among severely infected women and 3223.3 g in controls (P ¼ 0.08). Mean gestational age at delivery was 38.1 weeks versus 38.7 weeks (P ¼ 0.26).
Available data demonstrate that all patients in Seattle and 53/78 (68%) in Pittsburgh have clear documentation of receiving treatment with oseltamivir. A total of 49 women received oseltamivir within 48 h of symptom onset, whereas 25 women received it after 48 h. The primary reason (18/25 cases, 72%) for H1N1 influenza and pregnancy outcomes A Naresh et al delayed oseltamivir administration was presentation to care at 448 h after symptom onset. Women who received oseltamivir at 448 h after symptom onset delivered 1.2 weeks (95% CI 0.2, 2.3) earlier than women who received it at o48 h after symptom onset (P ¼ 0.02). Rates of preterm birth were 28.0% (95% CI 12.1%, 49.4%) in the delayed therapy group versus 12.2% (95% CI 4.6%, 24.8%) in the early therapy group (P ¼ 0.17). There was no difference in birth weight or incidence of SGA noted when comparing late versus early treatment. In all, 7% of participants were in the first trimester, 49% in the second trimester and 44% in the third trimester. Separate analysis of the impact of gestational age timing of infection did not detect any correlations to obstetric outcomes.
Discussion
This investigation demonstrates that for the majority of women with laboratory-confirmed 2009 H1N1 influenza, there were no significant differences in pregnancy outcomes compared with uninfected women. However, women with infection requiring hospitalization were statistically more likely to deliver infants who were SGA, and also had more than twice the rate of preterm birth (although it did not reach statistical significance). Interestingly, women who received delayed oseltamivir (448 h after onset of illness) delivered 41 week earlier than women who received early treatment. An additional intriguing finding is that women diagnosed with H1N1 were more likely to have underlying chronic health conditions. It is unclear whether this finding is because of varying clinician testing thresholds or inherent susceptibility to influenza illness among women with comorbid conditions. Much of the previous literature regarding influenza in pregnancy has focused primarily on maternal morbidity, and not specifically obstetric outcomes. Some recent investigations have examined the effect of seasonal influenza infection on obstetric outcomes. A randomized trial in Bangladesh demonstrated lower mean birth weight in infants of women who did not receive the seasonal influenza vaccine compared with women who were immunized. 19 Similarly, a large cohort study using a database from 44000 women conducted in Georgia, USA, demonstrated a significantly decreased incidence of prematurity and of SGA infants born to mothers who were vaccinated against seasonal influenza (OR 0.60, 95% CI 0.38, 0.94 for prematurity, OR 0.31, 95% CI 0.13, 0.75 for SGA). 9 Most recently, a large population-based study in the United States found an association between a clinical diagnosis of seasonal influenza and increased risk of SGA (OR 1.59, 95% CI 1.15, 2.20). 8 Conversely, a separate study failed to find differences in birth weight or preterm delivery among hospitalized pregnant women with seasonal influenza compared with matched controls. 20 Several recent reports have focused specifically on 2009 H1N1 influenza and pregnancy outcomes as well. A US case series of mostly hospitalized women with 2009 H1N1 noted a 30% preterm delivery rate. 4 Hospitalized women in the United Kingdom had a threefold increase in the risk of preterm delivery. 21 Similarly, a report from the Centers for Disease Control and Prevention H1N1 influenza and pregnancy outcomes A Naresh et al describing the outcomes of 347 critically ill women in the United States indicated that 64% of these women delivered before 37 weeks. 22 In addition, an investigation in Rhode Island women with influenza-like illness showed that birth weights were lower in the H1N1 influenza group compared with women with other causes of influenza-like illness. 23 The current study importantly differs from these previous investigations in that these new data represent a large cohort of women with predominantly mild laboratoryproven clinical influenza illness with few critically ill participants and employed a noninfected control group for robust statistical comparison.
There have been a number of investigations suggesting the benefits of early antiviral treatment on maternal outcomes. In the previously noted case series of predominantly hospitalized pregnant women in the United States, treatment with oseltamivir at o48 h after symptom onset was associated with a lower risk of hospital admission, intensive care unit admission and death. 4 A French registry-based study demonstrated that oseltamivir administration at 448 h after symptom onset was associated with intensive care unit admission. 24 A recent population-based study in the United States showed that pregnant women who started antiviral treatment 2 or more days after diagnosis were more likely to be hospitalized. 8 No prior studies have examined the effect of timing of oseltamivir administration on obstetric outcomes, although the results of the present study are not definitive in this regard. This study has many strengths. Most importantly, the current investigation includes only women with laboratory-confirmed influenza. This contrasts with nearly all previous studies that include women with symptoms suggestive of influenza without laboratory confirmation. This is a key distinction given the inherent inaccuracies of diagnoses based on clinical suspicion alone. The current study also importantly includes many women diagnosed and managed as outpatients (likely less ill) as well as women requiring hospitalization, thus providing a more thorough reflection of the entire influenza infection spectrum. In addition, these data are unique in that a matched site-specific large control group of noninfected pregnant women is included, allowing for direct comparisons of influenzainfected women with the general obstetric population. This feature enabled statistical methodology controlling for multiple confounding factors such as maternal comorbidity, increasing the certainty that the observed effects were because of influenza rather than the comorbid conditions themselves.
The current study also has some recognized limitations. The number of cases with severe H1N1 infection was relatively small. Information on some maternal characteristics, pregnancy outcomes and exact treatment details from outpatient settings was not available for every patient. This potentially limited the ability to control analyses for socioeconomic status and prepregnancy weight as well as analyze treatment specifics. Inpatient status may be an imperfect measure of severity of infection. In addition, the low number of outcomes in this data set of clinical entities, such as premature rupture of membranes, abruption, fetal anomalies, intrauterine deaths and deliveries at o24 weeks of gestation, did not allow for an assessment of an association between H1N1 influenza and these obstetric outcomes. As this was a retrospective cohort study, we are unable to definitively rule out for all participants whether a small fraction of the control patients were asymptomatically infected with H1N1 or whether they may have been treated at alternate facilities for H1N1. The separate laboratory methodologies for establishing a diagnosis of H1N1 (PCR vs RIDT) at different sites introduces variability, although both are considered valid methods of making a laboratory diagnosis of influenza. Finally, the large number of comparisons introduces the potential for type 1 error.
Despite these limitations, this study documents that compared with the general obstetric population, severe laboratory-confirmed H1N1 influenza infection in pregnancy was associated with an increased incidence of SGA infants. These findings lend further support to the recommendations of the American College of Obstetricians and Gynecologists and the Centers for Disease Control's Advisory Committee on Immunization Practices that all pregnant women receive the influenza vaccine and early antiviral therapy. 25, 26 Investigations into the mechanisms of these associations may delineate whether these are direct viral effects on the fetus or secondary consequences of maternal illness.
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